Global Personalized Cancer Vaccines Market, By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukaemia, Prostate Cancer, Cervical Cancer and Glioblastoma), Mechanism of Action Type (Tumour-associated Antigens (TAAs), Tumour-specific Antigens (TSAs), Somatic Mutations in Cancer Pharmacogenomics, Pharmacogenomics towards Genomic Polymorphism), Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines and Viral Vector and DNA Cancer Vaccines), Bio-maker Type (Pharmacogenomics, Prognostic and Predictive Biomarkers, Immune Checkpoint Biomarkers and Others), Treatment Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Route of Administration (Injectable and Others), End-Users (Hospitals, Homecare, Specialty Clinics and Others) – Industry Trends and Forecast to 2030.
Personalized Cancer Vaccines Market Analysis and Size
The global personalized cancer vaccines market is growing for several reasons, driven by advancements in cancer research, technology, and the increasing demand for personalized treatment options. Advances in genomics and the understanding of cancer at the molecular level have allowed researchers to identify specific genetic mutations and alterations that drive cancer growth. This knowledge has paved the way for personalized treatment approaches, including personalized cancer vaccines. Personalized cancer vaccines are designed to target specific antigens or mutations found in an individual patient's tumor. This tailored approach allows for more effective and precise treatment, potentially leading to better outcomes and fewer side effects compared to traditional cancer therapies.
Data Bridge Market Research analyses that the global personalized cancer vaccines market which was USD 2,34,790.00 million in 2022, is expected to reach USD 3,71,404.60 million by 2030, and is expected to undergo a CAGR of 5.9% during the forecast period of 2023 to 2030. “Corticosteroids” dominates the drugs segment of the global personalized cancer vaccines market owing to the increasing investment in healthcare. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Personalized Cancer Vaccines Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukaemia, Prostate Cancer, Cervical Cancer and Glioblastoma), Mechanism of Action Type (Tumour-associated Antigens (TAAs), Tumour-specific Antigens (TSAs), Somatic Mutations in Cancer Pharmacogenomics, Pharmacogenomics towards Genomic Polymorphism), Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines and Viral Vector and DNA Cancer Vaccines), Bio-maker Type (Pharmacogenomics, Prognostic and Predictive Biomarkers, Immune Checkpoint Biomarkers and Others), Treatment Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Route of Administration (Injectable and Others), End Users (Hospitals, Homecare, Specialty Clinics, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, Egypt, Rest of Middle East and Africa
|
|
Market Players Covered
|
Moderna, Inc. (U.S.), Gritstone Oncology (U.S.), Personalis Inc. (U.S.), Genocea (U.S.), CureVac AG (Germany), Celldex Therapeutics (U.S.), BioNTech SE (Germany), Advaxis, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Astrazeneca (UK), Pfizer Inc.(U.S.), Sanofi (France), Johnson & Johnson Services, Inc. (U.S.), AbbVie Inc. (U.S.), Allergan (Ireland), Merck & Co., Inc. (U.S.), Amgen Inc.(U.S.), Sun Pharmaceutical Industries Ltd.(India), Teva Pharmaceutical Industries Ltd. (Israel), Takeda Pharmaceutical Company Limited (Japan), GSK plc (U.K.), Cardinal Health (U.S.), Mylan N.V. (U.S.) and Boehringer Ingelheim International GmbH (Germany)
|
|
Market Opportunities
|
|
Market Definition
The global personalized cancer vaccines market is the industry involved in the development, production, and distribution of vaccines designed to treat cancer on an individualized or personalized basis. These vaccines are tailored to target specific cancer cells or antigens unique to a particular patient's tumor. Personalized cancer vaccines are part of the broader field of immunotherapy, which harnesses the patient's immune system to recognize and attack cancer cells.
Global Personalized Cancer Vaccines Market Dynamics
Drivers
- Advancements in Cancer Genomics
The increasing understanding of cancer at the genetic and molecular level has facilitated the identification of specific tumor antigens and genetic mutations, making it possible to create personalized vaccines that target these unique markers.
- Rising Cancer Incidence
The global burden of cancer continues to grow, driving the demand for more effective and targeted treatment options. Personalized cancer vaccines offer a promising approach to address the diverse and evolving nature of cancer.
Opportunity
- Targeted Therapies
Personalized cancer vaccines have the potential to provide highly targeted treatments with minimal off-target effects, offering an opportunity to improve patient outcomes while reducing side effects.
Furthermore, the rising collaboration, merger, and acquisition among the market players will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. In addition, rising number of market players will further expand the market's growth rate in the future.
Restraints/Challenges
- Complex Manufacturing
Personalized cancer vaccines are inherently complex to manufacture as they need to be tailored to each patient's unique tumor profile. This can be time-consuming and costly.
On the other hand, the high cost associated with the product manufacturing is expected to obstruct market growth. Also, the disruption in the supply chain industry has the potential to challenge the market’s growth. Also, lack of favorable reimbursement scenario and technology penetration in the developing economies, and lack of suitable infrastructure are projected to challenge the market in the forecast period of 2023-2030.
This global personalized cancer vaccines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global personalized cancer vaccines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- Increasing awareness regarding the prevention and elimination of cervical cancer is anticipated to fuel market growth. For instance, in June 2023, the University of Alabama at Birmingham entered into a partnership with the ACS and the Alabama Department of Public Health announced the launch of a state wide action plan as an elimination plan as a result of public health problems in Alabama
Global Personalized Cancer Vaccines Market Scope
The global personalized cancer vaccines market is segmented on the basis of cancer type, mechanism of action type, technology, bio-maker type, treatment type, route of administration, and end users. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Cancer Type
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Leukaemia
- Prostate Cancer
- Cervical Cancer
- Glioblastoma
Mechanism of Action Type
- Tumour-associated Antigens (TAAs)
- Tumour-specific Antigens (TSAs)
- Somatic Mutations in Cancer Pharmacogenomics
- Pharmacogenomics towards Genomic Polymorphism
Technology
- Dendritic Cells (DC) Cancer Vaccines
- Recombinant Cancer Vaccines
- Antigen/Adjuvant Cancer Vaccines
- Viral Vector and DNA Cancer Vaccines
Bio-Maker Type
- Pharmacogenomics
- Prognostic and Predictive Biomarkers
- Immune Checkpoint Biomarkers
- Others
Treatment Type
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
Route of Administration
- Injectables
- Others
End Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Global Personalized Cancer Vaccines Market Regional Analysis/Insights
Global personalized cancer vaccines market is analyzed, and market size insights and trends are provided by cancer type, mechanism of action type, technology, bio-maker type, treatment type, route of administration, and end users as referenced above.
The countries covered in the global personalized cancer vaccines market report are U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, Egypt, Rest of Middle East and Africa
North America dominates the global personalized cancer vaccines market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period of 2023 to 2030. This is due to the presence of FDA approved wound debridement devices and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, favourable health remuneration policies, rise in chronic wounds, and a growing elderly population will further propel the market's growth rate in this region.
Asia-Pacific is expected to be the fastest-growing region in the global personalized cancer vaccines market during the forecast period of 2023-2030 due to increase in the number of insurance payers in this region. Also, the development of private healthcare sector and rising awareness among the people will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global personalized cancer vaccines market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global personalized cancer vaccines market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global personalized cancer vaccines market. The data is available for historic period 2015-2020.
Competitive Landscape and Personalized Cancer Vaccines Market Share Analysis
The global personalized cancer vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global personalized cancer vaccines market.
Some of the major players operating in the global personalized cancer vaccines market are:
- Moderna, Inc. (U.S.)
- Gritstone Oncology (U.S.)
- Personalis Inc. (U.S.)
- Genocea (U.S.)
- CureVac AG (Germany)
- Celldex Therapeutics (U.S.)
- BioNTech SE (Germany)
- Advaxis, Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Astrazeneca (U.K.)
- Pfizer Inc.(U.S.)
- Sanofi (France)
- Johnson & Johnson Services, Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Allergan (Ireland)
- Merck & Co., Inc. (U.S.)
- Amgen Inc.(U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Takeda Pharmaceutical Company Limited. (Japan)
- GSK plc (U.K.)
- Cardinal Health (U.S.)
- Mylan N.V.(U.S.)
- Boehringer Ingelheim International GmbH (Germany)
SKU-